COVID-19 vaccines: keeping pace with SARS-CoV-2 variants

Muge Cevik; Nathan D. Grubaugh; Akiko Iwasaki; Peter Openshaw

doi:10.1016/j.cell.2021.09.010

COVID-19 vaccines: keeping pace with SARS-CoV-2 variants

Muge Cevik^*, Nathan D. Grubaugh, Akiko Iwasaki, Peter Openshaw

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

Abstract

As the SARS-CoV-2 pandemic evolves, new variants continue to emerge. Some highly transmissible variants, such as Delta, also raised concerns about the effectiveness provided by current vaccines. Understanding immunological correlates of protection and how laboratory findings correspond to clinical effectiveness is imperative to shape future vaccination strategies.

Original language	English
Pages (from-to)	5077-5081
Number of pages	5
Journal	Cell
Volume	184
Issue number	20
DOIs	https://doi.org/10.1016/j.cell.2021.09.010
Publication status	Published - 30 Sept 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

COVID-19

Access to Document

10.1016/j.cell.2021.09.010

Cite this

@article{8469b27c55194579b1aa9e3c7423220c,

title = "COVID-19 vaccines: keeping pace with SARS-CoV-2 variants",

abstract = "As the SARS-CoV-2 pandemic evolves, new variants continue to emerge. Some highly transmissible variants, such as Delta, also raised concerns about the effectiveness provided by current vaccines. Understanding immunological correlates of protection and how laboratory findings correspond to clinical effectiveness is imperative to shape future vaccination strategies.",

keywords = "COVID-19",

author = "Muge Cevik and Grubaugh, \{Nathan D.\} and Akiko Iwasaki and Peter Openshaw",

year = "2021",

month = sep,

day = "30",

doi = "10.1016/j.cell.2021.09.010",

language = "English",

volume = "184",

pages = "5077--5081",

journal = "Cell",

issn = "0092-8674",

publisher = "Elsevier",

number = "20",

}

TY - JOUR

T1 - COVID-19 vaccines

T2 - keeping pace with SARS-CoV-2 variants

AU - Cevik, Muge

AU - Grubaugh, Nathan D.

AU - Iwasaki, Akiko

AU - Openshaw, Peter

PY - 2021/9/30

Y1 - 2021/9/30

N2 - As the SARS-CoV-2 pandemic evolves, new variants continue to emerge. Some highly transmissible variants, such as Delta, also raised concerns about the effectiveness provided by current vaccines. Understanding immunological correlates of protection and how laboratory findings correspond to clinical effectiveness is imperative to shape future vaccination strategies.

AB - As the SARS-CoV-2 pandemic evolves, new variants continue to emerge. Some highly transmissible variants, such as Delta, also raised concerns about the effectiveness provided by current vaccines. Understanding immunological correlates of protection and how laboratory findings correspond to clinical effectiveness is imperative to shape future vaccination strategies.

KW - COVID-19

UR - https://www.scopus.com/pages/publications/85115085318

U2 - 10.1016/j.cell.2021.09.010

DO - 10.1016/j.cell.2021.09.010

M3 - Comment/debate

SN - 0092-8674

VL - 184

SP - 5077

EP - 5081

JO - Cell

JF - Cell

IS - 20

ER -

COVID-19 vaccines: keeping pace with SARS-CoV-2 variants

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this